On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...

Outlook Therapeutics ( ($OTLK) ) has provided an update. On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as Chairman ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

Short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) decreased during the last reporting period, falling from 4.13M to 3.51M. This put 21.82% of the company's publicly available shares short.

Outlook Therapeutics (OTLK) announced Faisal Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Sukhtian ...

OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earli ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...